Invasive pneumococcal diseases in Uruguayan children: Comparison between serotype distribution and conjugate vaccine formulations

Vaccine

Volumn 21, Issue 17-18, 2003, Pages 2093-2096

  Camou, T ^a   Palacio, R ^a   Di Fabio, J L ^b   Hortal, M ^c  

^a National Reference Laboratory   (Uruguay)

^b PAN AMERICAN HEALTH ORGANIZATION   (United States)

^c Ministry of Public Health Uruguay   (Uruguay)

Author keywords

Conjugate vaccine; Invasive pneumococcal infections; Streptococcus pneumoniae serotypes

Indexed keywords

STREPTOCOCCUS VACCINE;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG SURVEILLANCE PROGRAM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; URUGUAY;

EID: 0037449087     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00806-X     Document Type: Article

References (15)

1. Appelbaum P.C. Antimicrobial resístance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:1992;77-83.
2. Hortal M., Mogdasy C., Russi J.C., Deleon C., Suarez A. Microbial agents associated with pneumonia in children from Uruguay. Rev. Infect. Dis. 12(Suppl. 8):1990;S915-S922.
3. Kertez D.A., Di Fabio J.L., Cunto Brandileone M.C.et al. Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization Surveillance Study. Clin. Infect. Dis. 26:1998;1355-1361.
4. Butler JC, Epidemiology of pneumococcal serotypes and conjugate vaccine formulations. In: Tomasz A, editor. Molecular biology and mechanisms of disease. New York: Mary Ann Liebert Inc.; 1999. p. 479-84.
5. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Ninth information supplement M100-S9. Wayne (PA): National Committee for Clinical Laboratory Standards; 1999.
6. Di Fabio J.L., Homma A., De Quadros C. Pan American Health Organization Epidemiological Surveillance Network for Streptococcus pneumoniae. Microb. Drug. Resist. 3:1997;131-133.
7. Ruocco G., Curto S., Savio M., Laurani H., Frocht R. Impacto y experiencia de vacunacion contra Haemophilus influenzae tipo b. Rev. Panam. Salud. Publica. 5:1999;197-198.
8. Di Fabio J.L., Castañeda E., Agudelo C.I.et al. Evolution of Streptococcus pneumoniae serotypes and penicillin susceptibility in Latin America, Sireva-Vigia Group, 1993-1999. Pediatr. Infect. Dis. J. 20:2001;959-967.
9. Hausdorff W.P., Byant J., Paradiso P.R., Siber G.R. The contribution of specific pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use: Part I. Clin. Infect. Dis. 30:2000;100-121.
10. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Preventing pneumococcal disease among infants and young children. MMWR 2000;49:1-36.
11. Lipsit M. Bacterial vaccines and serotype replacement: lessons from H. influenzae and prospects for S. pneumoniae. Emerg. Infect. Dis. 5:1999;336-345.
12. Hortal M., Lovgren M., De la Hoz F.et al. Antibiotic resistance in Streptococcus pneumoniae in six Latin American countries: 1993-1999 surveillance. Microb. Drug. Resist. 7:2001;363-373.
13. Ogunniyi A.D., Folland R.L., Briles D.E., Hollingshead S.K., Paton J.C. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect. Immun. 68:2000;3028-3033.
14. Obaro S.K. Confronting the pnemococcus: a target shift or bullet change? Vaccine. 19:2001;1211-1217.
15. Scott J.A.G., Hall A.J., Dagan R.et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7000 episodes of invasive disease. Clin. Infect. Dis. 22:1996;973-981.